Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-06-28
2005-06-28
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S220000, C435S023000, C435S320100, C435S325000, C435S455000, C435S458000, C435S387000, C424S093100
Reexamination Certificate
active
06911203
ABSTRACT:
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
REFERENCES:
patent: 6485925 (2002-11-01), Duesbery et al.
Pugsley A. P. Bacterial toxins deliver the good, Proc. Natl. Acad. Sci. USA, 1996, 93, 8155-8156.
Duesbery N. S. et al., Anthrax lethal factor ccauses proteolytic inactivation of mitogen-activated protein kinase kinase, J. Appl. Microbiol., 1999, 87, 289-293.
Liu S. et al. Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin, J. Bilo. Chem 2001, 276, 17976-17984.
Duesbery N. S. et al., Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways, Proc. Natl. Acad. Sci. USA, 2001, 98, 4089-4094.
Dunn F. B. Anthrax as a Cancer Drug?, J. Natl. Cancer. Inst., 2001, 93, 1680-1681.
Koo H.-M. et al., Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase, Proc. Natl. Acad. Sci. USA, 2002, 99, 3052-3057.
Oka H. et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma, Cancer Res. 1995, 18, 4182-4187.
Duesbery, Nicholas S., et al. “Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor,”Science280:734-737 (May 1, 1998).
Duesbery, Nick S., et al. “CENP-E is an essential kinetochore motor in maturing oocytes and is masked during Mos-dependent, cell cycle arrest at metaphase II,”Proc. Natl. Acad. Sci. USA94:9165-9170 (Aug. 1997).
Kimpel, Kurt R., et al. “Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity,”Molecular Microbiology13(6):1093-1100 (1994).
Koo, Han-Mo, et al. “Enhanced Sensitivity to 1-β-D-Arabinofuranosylcytosine and Topoisomerase II Inhibitors in Tumor Cell Lines Harboring Activated ras Oncogenes,”Cancer Research56:5211-5216 (Nov. 15, 1996).
Menard, Armelle, et al. “The cytotoxic activity ofBacillus anthracislethal factor is inhibited by leukotriene A4hydrolase and metallopeptidase inhibitors,”Biochem. J. 320:687-691 (1996).
Weinstein, John N., et al. “An Information-Intensive Approach to the Molecular Pharmacology of Cancer,”Science275:343-349 (Jan. 17, 1997).
Duesbery Nicholas
Leppla Stephen
Vande Woude George
Webb Craig
Saidha Tekchand
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
Walicka Malgorzata A.
LandOfFree
Anthrax lethal factor is a MAPK kinase protease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anthrax lethal factor is a MAPK kinase protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthrax lethal factor is a MAPK kinase protease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3518190